Increased airway pressure due to superior mediastinal hematoma during endovascular coiling by transcarotid approach
An elderly woman with subarachanoid hemorrhage presented to our interventional neuroradiology suite for coil embolization of multiple intracranial aneurysms. The patient had difficult vascular access for the passage of microcatheter; hence, the embolization procedure was carried out with direct puncture of the left common carotid artery. During the procedure, the patient developed thromboembolism which was treated by administration of an antiplatelet agent, abciximab. At the end of procedure, she developed airway compromise due to extension of a local neck hematoma into the superior mediastinum. (Source: Journal of Clinical Anesthesia)
Source: Journal of Clinical Anesthesia - February 22, 2016 Category: Anesthesiology Authors: Priyanka Gupta, Girija Prasad Rath, Sujoy Banik, Charu Mahajan Tags: Case report Source Type: research
Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention.
CONCLUSIONS: Bivalirudin was associated with higher risk of suboptimal post-PCI TIMI flow but not with increased risk of acute or 30-day definite ST or one-year mortality compared with abciximab plus UFH or UFH alone.
PMID: 26865445 [PubMed - in process] (Source: EuroIntervention)
Source: EuroIntervention - February 13, 2016 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
CONCLUSIONS: Mutations of glycoproteins Ia, Ib, IIb and IIIa did not influence platelet aggregation in response to tirofiban in patients with unstable angina and non-ST-segment elevation myocardial infarction.
PMID: 26786608 [PubMed - as supplied by publisher] (Source: Sao Paulo Medical Journal)
Source: Sao Paulo Medical Journal - January 19, 2016 Category: Journals (General) Authors: Mansur AP, Roggerio A, Takada JY, Caribé PM, Avakian SD, Strunz CM Tags: Sao Paulo Med J Source Type: research
Optimisation of antithrombotic therapy in patients with acute coronary syndrome to reduce bleeding episodes
ConclusionThe multidisciplinary programme has been effective in reducing bleeding episodes. The interventions were effective in reducing antithrombotic drugs overdosage, incorporating the use of fondaparinux to the NSTE‐ACS therapeutic arsenal, limiting the use of bivalirudin with abciximab and obtaining body weight for most patients. (Source: International Journal of Clinical Practice)
Source: International Journal of Clinical Practice - December 28, 2015 Category: Internal Medicine Authors: A. Lorenzo‐Pinto, H. Bueno, B. Cuéllar‐Basterrechea, A. Herranz‐Alonso, C. Pérez‐Sanz, C. G. Rodríguez‐González, I. Iglesias‐Peinado, F. Fernández‐Avilés, M. Sanjurjo‐Sáez Tags: Original Paper Source Type: research
The P2Y 1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys
Abstract
Adenosine diphosphate directly induces platelet aggregation via the G-protein coupled P2Y1 and P2Y12 receptors. P2Y12, but not P2Y1, receptor antagonists are available in the clinic. The relevance of the P2Y1 receptor as an antiplatelet target has been studied in rodents, but not in higher species. We therefore examined effects of the pharmacological blockade of the P2Y1 receptor with its selective antagonist MRS2500 in monkey models of electrolytic-mediated arterial thrombosis (ECAT) and kidney bleeding time (KBT). Abciximab, a GPIIb-IIIa antagonist, and cangrelor, a P2Y12 antagonist, were utili...
Source: Journal of Thrombosis and Thrombolysis - December 12, 2015 Category: Hematology Source Type: research
Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
Abstract
The use of inhibitors of glycoprotein IIb/IIIa (GPIIb/IIIa) has provided dramatic results in terms of the prevention of acute stent thrombosis and a reduction in major adverse coronary events in patients subjected to percutaneous coronary intervention. GPIIb/IIIa or αIIbβ3 is a member of the β3 subfamily of integrins, which also includes αVβ3. GPIIb/IIIa functions as a receptor for fibrinogen and several adhesion proteins sharing an arginine-glycine-aspartic acid (RGD) sequence. GPIIb/IIIa antagonists, through blockade of the receptor, prevent platelet aggregation. Among the three GPIIb/IIIa ...
Source: Current Drug Metabolism - December 11, 2015 Category: Drugs & Pharmacology Authors: Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, Coscioni E, Romano S, Romano MF Tags: Curr Drug Metab Source Type: research
Microvascular obstruction after successful fibrinolytic therapy in acute myocardial infarction. Comparison of reteplase vs reteplase+abciximab: A cardiovascular magnetic resonance study.
CONCLUSION.: R+Abcx prevents MO: compared to traditional fibrinolytic therapy it allows better LV function and most likely improved long term survival.
PMID: 21977252 [PubMed] (Source: Heart International)
Source: Heart International - November 28, 2015 Category: Cardiology Tags: Heart Int Source Type: research
Thrombus aspiration in patients with large anterior myocardial infarction. A TASTE trial substudy
Conclusion In patients with STEMI and large area of myocardium at risk, TA did not affect outcome within one year. (Source: American Heart Journal)
Source: American Heart Journal - November 22, 2015 Category: Cardiology Source Type: research
Randomized evaluation of intralesion versus intracoronary abciximab and aspiration thrombectomy in patients with ST-elevation myocardial infarction: The COCTAIL II trial
Conclusions In patients with STEMI and high thrombotic burden, neither IL versus IC abciximab nor AT versus no aspiration reduced postprocedure intrastent atherothrombotic burden in patients with STEMI undergoing primary PCI. However, IL abciximab improved indices of angiographic and myocardial reperfusion compared to IC abciximab, benefits not apparent with AT. (Source: American Heart Journal)
Source: American Heart Journal - November 3, 2015 Category: Cardiology Source Type: research
Procedural and Clinical Outcomes after Use of the Glycoprotein IIb/IIIa inhibitor Abciximab for Saphenous Vein Graft Interventions
Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVG) poses a high-risk for distal coronary thromboembolic events. Glycoprotein IIb/IIIa inhibitors are frequently used in hope of reducing the impact of this, although the safety and efficacy of these drugs to improve outcomes in this setting are understudied. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - October 30, 2015 Category: Cardiology Authors: Ralf E. Harskamp, Niels Hoedemaker, L. Kristin Newby, Pier Woudstra, Maik J. Grundeken, Marcel A. Beijk, Jan J. Piek, Jan G. Tijssen, Rajendra H. Mehta, Robbert J. de Winter Source Type: research
Safety and Effectiveness of Adjunctive Intra-Arterial Abciximab in the Management of Acute Limb Ischemia
Contemporary endovascular management of acute limb ischemia (ALI) generally consists of tissue plasminogen activator (tPA) based catheter-directed thrombolysis (CDT) with or without pharmacomechanical thrombectomy (PMT). Although abciximab (Reopro), a GPIIb/IIIa receptor antagonist, is widely used in coronary revascularization, its safety and effectiveness in the treatment of ALI are unknown. Here, we review our contemporary experience with the endovascular management of ALI and assess the safety and effectiveness of abciximab. (Source: Annals of Vascular Surgery)
Source: Annals of Vascular Surgery - October 14, 2015 Category: Surgery Authors: Gregory G. Salzler, Ashley Graham, Peter H. Connolly, Darren B. Schneider, Andrew J. Meltzer Tags: Vascular & Endovascular Surgery Society Source Type: research
Safety and Effectiveness of Adjunctive Intraarterial Abciximab in the Management of Acute Limb Ischemia
Contemporary endovascular management of acute limb ischemia (ALI) generally consists of tissue plasminogen activator (tPA) based catheter-directed thrombolysis (CDT) with or without percutaneous mechanical thrombectomy (PMT). Although abciximab (Reopro), a GPIIb/IIIa receptor antagonist, is widely utilized in coronary revascularization, its safety and effectiveness in the treatment of ALI is unknown. Here we review our contemporary experience with the endovascular management of ALI and assess the safety and effectiveness of abciximab. (Source: Annals of Vascular Surgery)
Source: Annals of Vascular Surgery - October 14, 2015 Category: Surgery Authors: Gregory G. Salzler, Ashley Graham, Peter H. Connolly, Darren B. Schneider, Andrew J. Meltzer Source Type: research
Randomized Evaluation of Intralesion vs Intracoronary Abciximab and Aspiration Thrombectomy in Patients with STEMI: The COCTAIL II trial
Conclusions In patients with STEMI and high thrombotic burden, neither IL vs. IC abciximab nor AT vs. no aspiration reduced post procedure intra-stent athero-thrombotic burden in patients with STEMI undergoing primary PCI. However, IL abciximab improved indices of angiographic and myocardial reperfusion compared to IC abciximab, benefits not apparent with AT. (Source: American Heart Journal)
Source: American Heart Journal - September 11, 2015 Category: Cardiology Source Type: research
Successful Treatment of Myocardial Infarction in an Infant With Kawasaki Disease
This report describes successful treatment of myocardial infarction from coronary thrombosis in an infant with Kawasaki disease using intravenous tissue plasminogen activator and abciximab. (Source: Seminars in Cardiothoracic and Vascular Anesthesia)
Source: Seminars in Cardiothoracic and Vascular Anesthesia - August 18, 2015 Category: Anesthesiology Authors: Jone, P.-N., Tapia, D., Davidson, J., Fagan, T. E., Browne, L., Ing, R. J., Kay, J. Tags: Clinical Challenge Source Type: research
Intracoronary vs intravenous abciximab in interventional cardiology: A reopened question?
PMID: 26254107 [PubMed - as supplied by publisher] (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - August 4, 2015 Category: Drugs & Pharmacology Authors: Zimarino M, Radico F, Kristensen SD, De Caterina R Tags: Vascul Pharmacol Source Type: research
